2255311-93-2

2255311-93-2 structure
2255311-93-2 structure
  • Name: HPGDS inhibitor 3
  • Chemical Name: HPGDS inhibitor 3
  • CAS Number: 2255311-93-2
  • Molecular Formula: C21H27N3O2
  • Molecular Weight: 353.46
  • Catalog: Signaling Pathways Immunology/Inflammation PGE synthase
  • Create Date: 2022-05-21 08:51:54
  • Modify Date: 2024-01-12 07:34:08
  • HPGDS inhibitor 3 is an orally active and highly potent peripherally restricted hematopoietic prostaglandin D synthase (H-PGDS) inhibitor with IC50 value of 9.4 nM and EC50 of 42 nM. HPGDS inhibitor 3 exhibits good selectivity, good pharmacokinetic parameters in mouse, rat, and dog, and no CNS toxicity. HPGDS inhibitor 3 has anti-inflammatory activity[1].

Name HPGDS inhibitor 3
Description HPGDS inhibitor 3 is an orally active and highly potent peripherally restricted hematopoietic prostaglandin D synthase (H-PGDS) inhibitor with IC50 value of 9.4 nM and EC50 of 42 nM. HPGDS inhibitor 3 exhibits good selectivity, good pharmacokinetic parameters in mouse, rat, and dog, and no CNS toxicity. HPGDS inhibitor 3 has anti-inflammatory activity[1].
Related Catalog
Target

IC50: 9.4 nM (H-PGDS)[1] EC50: 42 nM (H-PGDS)[1]

In Vivo HPGDS inhibitor 3 (compound 1y) (1-3 mg/kg; PO and IV; single) has a lower IV clearance, similar steady state volume of distribution, longer terminal half-life, and high oral bioavailability, as well as very low brain exposures in mouse, rat and dog[1]. HPGDS inhibitor 3 (0.003-1 mg/kg; PO; single) attenuates PGD2 release to baseline levels in a dose-dependent manner[1]. HPGDS inhibitor 3 (0.003-1 mg/kg; PO; single) inhibits LPS-induced PGD2 increase in plasma and skeletal muscle in a dose-dependent manner[1]. HPGDS inhibitor 3 (1, 3, and 10 mg/kg; PO; q.d., for 16 days) significantly enhances functional recovery of injured limbs, and hastens the time to full functional recovery of injured limb muscles[1]. HPGDS inhibitor 3 (10, 30 and 100 mg/kg; PO; once daily, for 7 days) exhibits well tolerated at 30 mg/kg/day in rat but not tolerated at 100 mg/kg/day[1]. HPGDS inhibitor 3 (10, 30, and 75 mg/kg; PO; once daily, for 4 days) shows well tolerated at 30 mg/kg/day in dogs but not tolerated at 75 mg/kg/day[1]. Pharmacokinetic Parameters of HPGDS inhibitor 3 in mice, rats and dogs[1]. Mouse IV, 1 mg/kg PO, 3 mg/kg Rat IV, 0.4 mg/kg PO, 2.4 mg/kg Dog IV, 0.5 mg/kg PO, 1 mg/kg T1/2 (h) 2.9 5.1 6.2 CL (mL/min/kg) 9.0 4.5 1.9 Vss (L/kg) 1.6 1.6 1.0 F (%) 71 100 92 Brain:blood ratio 0.06
References

[1]. Cadilla R, Deaton DN, Do Y, et al. The exploration of aza-quinolines as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors with low brain exposure. Bioorg Med Chem. 2020;28(23):115791.

Molecular Formula C21H27N3O2
Molecular Weight 353.46
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.